The degree of microRNA-34b/c methylation in serum-circulating DNA is associated with malignant pleural mesothelioma

Lung Cancer

Volumn 82, Issue 3, 2013, Pages 485-490

  Muraoka, Takayuki ^a   Soh, Junichi ^a   Toyooka, Shinichi ^a   Aoe, Keisuke ^b   Fujimoto, Nobukazu ^c   Hashida, Shinsuke ^a   Maki, Yuho ^a   Tanaka, Norimitsu ^a   Shien, Kazuhiko ^a   Furukawa, Masashi ^a   Yamamoto, Hiromasa ^a   Asano, Hiroaki ^a   Tsukuda, Kazunori ^a   Kishimoto, Takumi ^c   Otsuki, Takemi ^d   Miyoshi, Shinichiro ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b NATIONAL SANYO HOSPITAL   (Japan)

^c OKAYAMA ROSAI HOSPITAL   (Japan)

^d KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Circulating DNA; Digital PCR; Malignant pleural mesothelioma; Methylation; MicroRNA; MiR 34b c

Indexed keywords

ASBESTOS; CIRCULATING DNA; MICRORNA; MICRORNA 34B; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ARTICLE; CANCER PROGNOSIS; CONTROLLED STUDY; DNA EXTRACTION; DNA METHYLATION; FEMALE; GENETIC ASSOCIATION; HUMAN; INVERSE POLYMERASE CHAIN REACTION; MALE; MELTING POINT; NONHUMAN; PATHOGENESIS; PLEURA MESOTHELIOMA; PLEURISY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC;

CIRCULATING DNA; DIGITAL PCR; MALIGNANT PLEURAL MESOTHELIOMA; METHYLATION; MICRORNA; MIR-34B/C;

ADULT; AGED; AGED, 80 AND OVER; DNA; DNA METHYLATION; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MICRORNAS; MIDDLE AGED; NEOPLASM STAGING; PLEURAL NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84887606518     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.09.017     Document Type: Article

References (37)

1. La Vecchia C., Boffetta P. Role of stopping exposure and recent exposure to asbestos in the risk of mesothelioma. Eur J Cancer Prev 2012, 21:227-230.
2. Robinson B.W., Lake R.A. Advances in malignant mesothelioma. N Engl J Med 2005, 353:1591-1603.
3. Tsao A.S., Wistuba I., Roth J.A., Kindler H.L. Malignant pleural mesothelioma. J Clin Oncol 2009, 27:2081-2090.
4. Fennell D.A., Gaudino G., O'Byrne K.J., Mutti L., van Meerbeeck J. Advances in the systemic therapy of malignant pleural mesothelioma. Nat Clin Pract Oncol 2008, 5:136-147.
5. Hooper C., Lee Y.C., Maskell N. Investigation of a unilateral pleural effusion in adults: British Thoracic Society Pleural Disease Guideline 2010. Thorax 2010, 65(Suppl. 2):ii4-ii17.
6. Scherpereel A., Astoul P., Baas P., Berghmans T., Clayson H., de Vuyst P., et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J 2010, 35:479-495.
7. Ray M., Kindler H.L. Malignant pleural mesothelioma: an update on biomarkers and treatment. Chest 2009, 136:888-896.
8. Davies H.E., Nicholson J.E., Rahman N.M., Wilkinson E.M., Davies R.J., Lee Y.C. Outcome of patients with nonspecific pleuritis/fibrosis on thoracoscopic pleural biopsies. Eur J Cardiothorac Surg 2010, 38:472-477.
9. Creaney J., Olsen N.J., Brims F., Dick I.M., Musk A.W., de Klerk N.H., et al. Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma. Cancer Epidemiol Biomarkers Prev 2010, 19:2238-2246.
10. van der Bij S., Schaake E., Koffijberg H., Burgers J.A., de Mol B.A., Moons K.G. Markers for the non-invasive diagnosis of mesothelioma: a systematic review. Br J Cancer 2011, 104:1325-1333.
11. Kimura K., Toyooka S., Tsukuda K., Yamamoto H., Suehisa H., Soh J., et al. The aberrant promoter methylation of BMP3b and BMP6 in malignant pleural mesotheliomas. Oncol Rep 2008, 20:1265-1268.
12. Tomii K., Tsukuda K., Toyooka S., Dote H., Hanafusa T., Asano H., et al. Aberrant promoter methylation of insulin-like growth factor binding protein-3 gene in human cancers. Int J Cancer 2007, 120:566-573.
13. Toyooka S., Carbone M., Toyooka K.O., Bocchetta M., Shivapurkar N., Minna J.D., et al. Progressive aberrant methylation of the RASSF1A gene in simian virus 40 infected human mesothelial cells. Oncogene 2002, 21:4340-4344.
14. Ambros V. MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. Cell 2003, 113:673-676.
15. Toyota M., Suzuki H., Sasaki Y., Maruyama R., Imai K., Shinomura Y., et al. Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res 2008, 68:4123-4132.
16. Kubo T., Toyooka S., Tsukuda K., Sakaguchi M., Fukazawa T., Soh J., et al. Epigenetic silencing of microRNA-34b/c plays an important role in the pathogenesis of malignant pleural mesothelioma. Clin Cancer Res 2011, 17:4965-4974.
17. Grigoriu B.D., Scherpereel A., Devos P., Chahine B., Letourneux M., Lebailly P., et al. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res 2007, 13:2928-2935.
18. Gube M., Taeger D., Weber D.G., Pesch B., Brand P., Johnen G., et al. Performance of biomarkers SMRP, CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung cancer in a cohort of workers formerly exposed to asbestos. Arch Toxicol 2011, 85:185-192.
19. Pass H.I., Levin S.M., Harbut M.R., Melamed J., Chiriboga L., Donington J., et al. Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med 2012, 367:1417-1427.
20. Hollevoet K., Reitsma J.B., Creaney J., Grigoriu B.D., Robinson B.W., Scherpereel A., et al. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol 2012, 30:1541-1549.
21. Leon S.A., Shapiro B., Sklaroff D.M., Yaros M.J. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 1977, 37:646-650.
22. Jahr S., Hentze H., Englisch S., Hardt D., Fackelmayer F.O., Hesch R.D., et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001, 61:1659-1665.
23. Gormally E., Caboux E., Vineis P., Hainaut P. Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. Mutat Res 2007, 635:105-117.
24. Paci M., Maramotti S., Bellesia E., Formisano D., Albertazzi L., Ricchetti T., et al. Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer. Lung Cancer 2009, 64:92-97.
25. Horlitz M., Lucas A., Sprenger-Haussels M. Optimized quantification of fragmented, free circulating DNA in human blood plasma using a calibrated duplex real-time PCR. PLoS One 2009, 4:e7207.
26. Vogelstein B., Kinzler K.W. Digital PCR. Proc Natl Acad Sci USA 1999, 96:9236-9241.
27. Pohl G., Shih Ie M. Principle and applications of digital PCR. Expert Rev Mol Diagn 2004, 4:41-47.
28. Yung T.K., Chan K.C., Mok T.S., Tong J., To K.F., Lo Y.M. Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. Clin Cancer Res 2009, 15:2076-2084.
29. Weisenberger D.J., Trinh B.N., Campan M., Sharma S., Long T.I., Ananthnarayan S., et al. DNA methylation analysis by digital bisulfite genomic sequencing and digital MethyLight. Nucleic Acids Res 2008, 36:4689-4698.
30. Sirera R., Bremnes R.M., Cabrera A., Jantus-Lewintre E., Sanmartin E., Blasco A., et al. Circulating DNA is a useful prognostic factor in patients with advanced non-small cell lung cancer. J Thorac Oncol 2011, 6:286-290.
31. Li L., Choi J.Y., Lee K.M., Sung H., Park S.K., Oze I., et al. DNA methylation in peripheral blood: a potential biomarker for cancer molecular epidemiology. J Epidemiol 2012, 22:384-394.
32. Snell C., Krypuy M., Wong E.M., Loughrey M.B., Dobrovic A. BRCA1 promoter methylation in peripheral blood DNA of mutation negative familial breast cancer patients with a BRCA1 tumour phenotype. Breast Cancer Res 2008, 10:R12.
33. Shen J., Todd N.W., Zhang H., Yu L., Lingxiao X., Mei Y., et al. Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. Lab Invest 2011, 91:579-587.
34. Fischer J.E., Bachmann L.M., Jaeschke R. A readers' guide to the interpretation of diagnostic test properties: clinical example of sepsis. Intensive Care Med 2003, 29:1043-1051.
35. Tanaka N., Toyooka S., Soh J., Kubo T., Yamamoto H., Maki Y., et al. Frequent methylation and oncogenic role of microRNA-34b/c in small-cell lung cancer. Lung Cancer 2012, 76:32-38.
36. Wang Z., Chen Z., Gao Y., Li N., Li B., Tan F., et al. DNA hypermethylation of microRNA-34b/c has prognostic value for stage non-small cell lung cancer. Cancer Biol Ther 2011, 11:490-496.
37. Suzuki H., Yamamoto E., Nojima M., Kai M., Yamano H.O., Yoshikawa K., et al. Methylation-associated silencing of microRNA-34b/c in gastric cancer and its involvement in an epigenetic field defect. Carcinogenesis 2010, 31:2066-2073.